In a retrospective review of 2276 patients with acute myeloid leukemia (AML) treated on one of three consecutive Phase 3 studies using non-age based, standard intensive chemotherapy conducted by the Japan Adult Leukemia Study Group between 1995 and 2005, there was a significant decline in overall survival in patients aged ≥ 50 years when compared to those < 50 years.
In a retrospective review of 2276 patients with acute myeloid leukemia (AML) treated on one of three consecutive Phase 3 studies using non-age based, standard intensive chemotherapy conducted by the Japan Adult Leukemia Study Group between 1995 and 2005, there was a significant decline in overall survival in patients aged ≥ 50 years when compared to those < 50 years.
Treatment of AML Based on Age
November 1, 2013